Regeneron First-Quarter Profit Tops Estimates on EyleaMeg Tirrell
Regeneron Pharmaceuticals Inc., maker of the eye medicine Eylea, reported first-quarter profit that topped analysts’ estimates and increased its U.S. sales forecast for the drug. The shares rose.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.